Eli Lilly and Co
Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals
Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday. “If our ambition is to help hundreds of millions of patients out there, then we need not just the best, but the broadest pipeline in the world,” said Novo Nordisk CEO […]
Read More
Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the […]
Read More
Iran tensions, Palantir earnings, Musk’s SEC settlement and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. Yesterday was a busy day for Amazon‘s top brass: CEO Andy Jassy joined CNBC’s “Mad Money,” while executive chairman Jeff Bezos was the honorary co-chair and lead sponsor of last night’s Met Gala. Stock futures are rising this morning after […]
Read More
Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly’s GLP-1 dominance
Still life of the new Wegovy semaglutide tablets on a white background. Its a prescription medicine used with a reduced calorie diet and .and physical activity. Michael Siluk | Universal Images Group | Getty Images When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight. LifeMD went from seeing […]
Read More
‘Bubble effect’: Weight loss drug fueled growth is putting the pharma sector at risk, report finds
Surging demand for weight loss and diabetes drugs leaves the pharmaceutical sector at risk from a “bubble effect” as profitability soars, new research suggests. Demand for the likes of Wegovy and Zepbound has driven research and development returns to their highest level in years, but a report published by Deloitte on Monday suggests this is […]
Read More
Weight loss and hair loss: The growing hair treatment market from GLP-1s
When Branneisha Cooper first began taking GLP-1 injection Mounjaro in late 2022, she heard online that she could experience temporary hair thinning and prepared for the worst. But it would take about a year before she began noticing her hair falling out in clumps. Cooper said it was especially shocking because she has always had […]
Read More
Apple earnings, DHS shutdown, ‘Ozempic breath’ and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Friday. My colleagues and I will be covering Berkshire Hathaway‘s annual meeting tomorrow — its first without Warren Buffett as CEO. You can follow along with our special coverage on TV and online. S&P 500 futures are little changed this morning […]
Read More
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Thursday proposed excluding the active ingredients in Novo Nordisk and Eli Lilly‘s blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding […]
Read More
More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says
More than 20,000 people have started taking Eli Lilly‘s GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. The FDA approved Lilly’s once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk’s Wegovy pill. Investors have been closely tracking […]
Read More
Stocks making the biggest moves premarket: Meta, Eli Lilly, Caterpillar, Amazon & more
Check out the companies making the biggest moves in premarket trading: Meta Platforms — The Facebook parent dropped 9% after the company hiked its full-year capital expenditures guidance to a range of $125 billion to $145 billion, raising concern over its AI spending. That forecast overshadowed a better-than-expected Q1 report. Eli Lilly — The Zepbound […]
Read More